123I-vasoactive intestinal peptide (VIP) receptor scanning: Update of imaging results in patients with adenocarcinomas and endocrine tumors of the gastrointestinal tract☆
References (44)
- et al.
Vasoactive intestinal peptide and watery diarrhea syndrome
Lancet
(1973) - et al.
A human somatostatin receptor (SSTR3), located on chromosome 22, displays preferential affinity for somatostatin-14-like peptides
FEBS
(1993) - et al.
Solubilization of the liver vasoactive intestinal peptide receptors
J. Biol. Chem.
(1986) - et al.
Purification of vasoactive intestinal peptide receptor from porcine liver by a newly designed one-step affinity chromatography
J. Biol. Chem.
(1990) - et al.
Human intestinal VIP receptor: Cloning and functional expression of two cDNA encoding proteins with different N-terminal domains
Biochem. Biophys. Res. Commun.
(1994) - et al.
Localization of endocrine-related tumours with radioiodinated analogue of somatostatin
Lancet
(1989) - et al.
Combined use of 111In-DTPA-D-Phe-1-octreotide and 123I-vasoactive intestinal peptide (VIP) in the localization diagnosis of medullary thyroid carcinoma (MTC)
Nucl. Med. Biol.
(1996) - et al.
The VIP2 receptor: Molecular characterization of a cDNA encoding a novel receptor for vasoactive intestinal peptide
FEBS Lett.
(1993) - et al.
Pharmacological characterization of the novel helodermin/VIP receptor present in human SUP-T1 lymphoma cell membranes
Regul. Pept.
(1989) - et al.
Molecular cloning and functional characterization of a human VIP receptor from sup-T1 lymphoblasts
Biochem. Biophys. Res. Commun.
(1994)
Islet cell tumor and a syndrome of refractory watery diarrhea and hypokalemia
Am. J. Med.
(1958)
Characterization of prostaglandin binding sites expressed on human blood basophils: Evidence for a prostaglandin E1, I2 and D2 receptor
J. Biol. Chem.
(1992)
Cloning, functional expression and pharmacological characterization of a fourth (hSSTR4) and fifth (hSSTR5) human somatostatin receptor subtype
Biochem. Biophys. Res. Commun.
(1993)
Cloning of a novel somatostatin receptor, SST3, coupled to adenylate cyclase
J. Biol. Chem.
(1992)
Solubilization of the vasoactive intestinal peptide receptor from human colonic adenocarcinoma cells
J. Biol. Chem.
(1988)
Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone
Science
(1973)
Vasoactive intestinal peptide stimulates protein phosphorylation in a colonic epithelial cell line
Am. J. Physiol.
(1987)
The human vasoactive intestinal peptide receptor: Molecular identification by covalent cross-linking in colonic epithelium
J. Clin. Endocrinol. Metab.
(1985)
Cloning and expression of a human somatostatin-14-selective receptor variant (somatostatin receptor 4) located on chromosome 20
Mol. Pharmacol.
(1993)
Pharmacology, molecular identification and functional characteristics of vasoactive intestinal peptide receptors in human breast cancer
Cancer Res.
(1988)
VIP: Molecular biology and neurobiological function
Mol. Neurobiol.
(1989)
Cloning and functional characterization of a third pituitary adenylate cyclase-activating polypeptide subtype expressed in insulin-secreting cells
Cited by (48)
Imaging of Neuroendocrine Tumors
2007, Hematology/Oncology Clinics of North AmericaCitation Excerpt :Compared with CT and MRI, MIBG has high specificity, with reports up to 99% [15]. I-123 labeled VIP has been reported to localize intestinal adenocarcinomas and endocrine tumors and their metastases, with overall 74% sensitivity [75]. TP3754, a Tc-99m–labeled VIP with promising imaging characteristics, has been developed and is under evaluation [76].
Preparation of the novel fluorine-18-labeled VIP analog for PET imaging studies using two different synthesis methods
2007, Journal of Fluorine ChemistryNuclear medicine in the detection and management of pancreatic islet-cell tumours
2005, Best Practice and Research: Clinical Endocrinology and Metabolism<sup>177</sup>Lu-DOTA-lanreotide: A novel tracer as a targeted agent for tumor therapy
2004, Nuclear Medicine and BiologyTumour therapy with radiolabelled peptides: Current status and future directions
2004, Digestive and Liver Disease
- ☆
These studies were supported in part by a Foundation of the Mayor of the City of Vienna (Bürgermeisterfonds), the Austrian National Bank, the Ludwig Boltzmann Institute for Nuclear Medicine, and the Anniversary Foundation (Hochschuljubiläumsfonds) of the University of Vienna.
Copyright © 1996 Published by Elsevier Inc.